Open AccessThe role of EGFR mutation testing in the choice for surgical tactics in NSCLC treatment
Author(s) -
Evgeniy Slugin,
Evgeniy Levchenko,
E.N. Imyanitov,
O. O. Lopushanskaya
Publication year - 2021
Publication title -
voprosy onkologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 11
eISSN - 2949-4915
pISSN - 0507-3758
DOI - 10.37469/0507-3758-2021-67-3-315-322
Subject(s) - medicine , lung cancer , mutation , oncology , epidermal growth factor receptor , disease , cancer , acquired resistance , intensive care medicine , gene , biology , genetics
Lung cancer is the most commonly diagnosed cancer in the world, and currently the mortality rate from this disease is one of the highest. The detection of EGFR mutation plays an important role in the choice of treatment in clinical practice. As already known, over the past decade, EGFR mutations have been a predictive factor for the prescription of tyrosine kinase inhibitors (EGFR TKIs) in patients with advanced non-small cell lung cancer (NSCLC). The role of EGFR mutation as a prognostic factor for patients undergoing surgery and the possibility of using surgery to overcome the resistance mechanisms that develop in response to EGFR TKIs remain unexplored. This literature review examines key aspects of the EGFR mutation as a factor that can influence the treatment and using the surgical method.